Bhathika Perera

Bhathika Perera

Auto-generated profile, based on publicly available information

Bhathika Perera

University College London

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2019 in British Journal of Learning Disabilities
Verified
Journal Article
Closed access
PDF file
BPBhathika Perera
Bhathika Perera
SASalma Audi
Salma Audi
SSSolomis Solomou
Solomis Solomou
KCKen Courtenay
Ken Courtenay
HRHugh Ramsay
Hugh Ramsay

16 October 2020 in BJPsych Open
Verified
Journal Article
Open access
PDF file
BPBhathika Perera
Bhathika Perera
RLRichard Laugharne
Richard Laugharne
WHWilliam Henley
William Henley
AZAbigail Zabel
Abigail Zabel
KLKirsten Lamb
Kirsten Lamb
SRShankar Rohit
Shankar Rohit
Background: Rapid spread of coronavirus disease 2019 (COVID-19) has affected people with intellectual disability disproportionately. Existing data does not provide enough information to understand factors associated with increased deaths in those with intellectual disability. Establishing who is at high risk is important in developing prevention strategies, given risk factors or comorbidities in people with intellectual disability may be different to those in the general population. Aims: To identify comorbidities, demographic and clinical factors of those individuals with intellectual disability who have died from COVID-19. Method: An observational descriptive case series looking at deaths because of COVID-19 in people with intellectual disability was conducted. Along with established risk factors observed in the general population, possible specific risk factors and comorbidities in people with intellectual disability for deaths related to COVID-19 were examined. Comparisons between mild and moderate-to-profound intellectual disability subcohorts were undertaken. Results: Data on 66 deaths in individuals with intellectual disability were analysed. This group was younger (mean age 64 years) compared with the age of death in the general population because of COVID-19. High rates of moderate-to-profound intellectual disability (n = 43), epilepsy (n = 29), mental illness (n = 29), dysphagia (n = 23), Down syndrome (n = 20) and dementia (n = 15) were observed. Conclusions: This is the first study exploring associations between possible risk factors and comorbidities found in COVID-19 deaths in people with intellectual disability. Our data provides insight into possible factors for deaths in people with intellectual disability. Some of the factors varied between the mild and moderate-to-profound intellectual disability groups. This highlights an urgent need for further systemic inquiry and study of the possible cumulative impact of these factors and comorbidities given the possibility of COVID-19 resurgence.

30 May 2022 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Open access
LWL.V. Watkins
L.V. Watkins
WHW. Henley
W. Henley
JSJ.J. Sun
J.J. Sun
BPB. Perera
B. Perera
HAH. Angus-Leppan
H. Angus-Leppan
SRShankar Rohit
Shankar Rohit
People with intellectual disabilities (ID) suffer multimorbidity, polypharmacy and excess mortality at a younger age than general population. Those with ID and epilepsy are at higher risk of worse clinical outcomes than their peers without epilepsy. In the ID population the health profile of those aged ≥40 years can be compared to those aged over 65 in the general population. To date there is limited data available to identify clinical characteristics and risk factors in older adults (≥40 years) with ID and epilepsy. The Epilepsy in ID National Audit (Epi-IDNA) identified 904 patients with ID and epilepsy from 10 sites in England and Wales. This subsequent analysis of the Epi-IDNA cohort compared the 405 adults over 40 years with 499 adults ≥18 years aged under 40 years. Comparison was made between clinical characteristics and established risk factors using the Sudden Unexpected Death in Epilepsy (SUDEP) and Seizure Safety Checklist. The older adults' cohort had significantly higher levels of co-morbid physical health conditions, mental health conditions, anti-seizure medications (median 5), and antipsychotics compared to the younger cohort. The older group were significantly less likely to be diagnosed with a co-morbid neurodevelopmental disorder, and to have an epilepsy care plan. This is the largest study to date focused on adults with ID and epilepsy over 40 years. The ≥40 years cohort compared to the younger group has higher levels of clinical risk factors associated with multi-morbidity, potential iatrogenic harm and premature mortality with worse clinical oversight mechanisms.

23 December 2021 in Bjpsych Bulletin
Verified
Journal Article
Open access
PDF file
LKLaura Korb
Laura Korb
DODavid O'Regan
David O'Regan
JCJane Conley
Jane Conley
EDEmma Dillon
Emma Dillon
RBRachel Briggs
Rachel Briggs
BPBhathika Perera
Bhathika Perera
Sleep is vital for our physical and mental health. Studies have shown that there is a high prevalence of sleep disorders and sleep difficulties amongst adults with intellectual disabilities. Despite this, sleep is often overlooked or its disorders are considered to be difficult to treat in adults with intellectual disabilities. There is a significant amount of research and guidance on management of sleep disorders in the general population. However, the evidence base for sleep disorders in adults with intellectual disabilities is limited. In this review paper, we look at the current evidence base for sleep disorders in adults with an intellectual disability, discuss collaborative working between intellectual disabilities psychiatrists and sleep medicine specialists to manage sleep disorders, and provide recommendations for future directions.

5 December 2019 in Journal of Intellectual Disability Research
Verified
Journal Article
Closed access
PDF file
BPB. Perera
B. Perera
KCK. Courtenay
K. Courtenay
SSS. Solomou
S. Solomou
ABA. Borakati
A. Borakati
ASAndre Strydom
Andre Strydom

6 December 2021 in BJPsych Open
Verified
Journal Article
Open access
PDF file
DNDanial Naqvi
Danial Naqvi
BPBhathika Perera
Bhathika Perera
SMSarah Mitchell
Sarah Mitchell
RSRory Sheehan
Rory Sheehan
SRShankar Rohit
Shankar Rohit
Background: Coronavirus disease 2019 (COVID-19) has had a disproportionate impact on people with intellectual disability (PwID). PwID are at higher risk of mental illness and receive psychotropic prescribing ‘off licence' also, to manage distress behaviour. The lockdown and reduction of multidisciplinary face-to-face appointments had an impact on care delivery, the recourse possibly being psychotropic prescribing. It is imperative to comprehend the influence the pandemic had on psychotropic prescribing patterns to enable future planning.Aims: The aim was to understand the impact of the pandemic by comparing psychotropic prescribing patterns during the England lockdown with the prescribing patterns before lockdown in specialist urban and rural psychiatric services for PwID.Method: Data was collected from Cornwall (rural) and London (urban) intellectual disability services in England as a service evaluation project to rationalise psychotropic prescribing. PwID in both services open across January 2020 to January 2021 were included. Baseline patient demographics including age, gender, ethnicity, intellectual disability level and neurodevelopmental and psychological comorbidities were collected. Baseline psychotropic prescribing and subsequent % change for each psychotropic group for the two services was compared using Pearson's chi-square and z-statistic (two tailed) with significance taken at P < 0.05.Results: The two centres London (n = 113) and Cornwall (n = 97) were largely comparable but for baseline differences in terms of presence of severe mental illness (37 v. 86, P < 0.001), challenging behaviour (44 v. 57, P < 0.05) and attention-deficit hyperactivity disorder (37 v. 3, P < 0.001). There was an overall increase in psychotropic prescribing during lockdown in urban as compared with rural settings (11% v. 2%).Conclusions: The pandemic caused an increase in psychotropic prescribing associated with lockdown severity and urban settings. Team structures could have played a role.